Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials Academic Article Article uri icon

Overview

MeSH Major

  • Chickenpox Vaccine
  • HIV Infections
  • Measles-Mumps-Rubella Vaccine
  • Mumps
  • Rubella
  • Vaccination

abstract

  • Efficacy responses with darunavir-ritonavir 600/100 mg twice daily plus optimised background regimen were greater than those with control PI and were sustained to at least week 48, with favourable safety and tolerability in treatment-experienced patients. This regimen could expand the treatment options available for such patients.

publication date

  • April 7, 2007

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(07)60497-8

PubMed ID

  • 17416261

Additional Document Info

start page

  • 1169

end page

  • 78

volume

  • 369

number

  • 9568